నైరూప్య

Inhibition of cisplatin-resistant tumor cells on activated CD4+ T cells in ovarian cancer and its mechanism

Li H*, Tian S, Liu Z, Yu J & Yan J

Objective: To investigate the inhibition of cisplatin-resistant tumor cells on activated CD4+ T cells in ovarian cancer and its mechanism.

Methods: 50 patients with ovarian cancer admitted to our hospital from March 2016 to July 2017 were selected as the research group, and 50 normal subjects were selected as the control group. The same separation method of CD4+ T cells was applied to both two groups. The serum levels of ovarian cancer markers and inflammation factors were compared between two groups.

Results: The serum levels of ovarian cancer markers in the research group were higher than those in the control group (P<0.05). The average proportion of CD4+ T cells in peasant patients was higher than that in workers and cadres (P<0.05). The average proportion of CD4+ T cells in patients with tumor infiltration was higher than that in patients without infiltration (P<0.05). The level of IL-6 in the research group was higher than that in the control group. While the levels of IL-10, IL-4, IL-2, TNF-α and IFN-γ were lower than those in the control group (P<0.05), and the immune function of the research group was still lower than that of the control group (P<0.05).

Conclusion: Cisplatin-resistant ovarian cancer cells can inhibit the activation of CD4+ T cells, which can effectively judge the different stages of ovarian cancer. Moreover, the number of CD4+ T cells can be used to determine the prognosis of patients, providing a certain clue for clinical treatment.